Evotec SE (EVO) said Tuesday that it has advanced its neuroscience collaboration with Bristol Myers Squibb (BMY) by securing a research payment of $20 million for further development of a pre-clinical program in neurodegeneration.
The two companies started their collaboration in December 2016 to develop transformative treatments that can slow or halt disease progression for a broad range of neurodegenerative diseases.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.